Compare Johnson & Johnson (JNJ) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Tripadvisor Inc Common Stock — how do they compare? Johnson & Johnson trades at $249.59 (market cap $598.96B), while Tripadvisor Inc Common Stock trades at $13.9 (market cap $1.68B). The key difference: Johnson & Johnson is far larger — about 356.5× Tripadvisor Inc Common Stock's market cap, and Johnson & Johnson pays a 2.15% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| JNJ | TRIP | |
|---|---|---|
Market Cap | $598.96B | $1.68B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $19.14 |
52-Week Low | $164.36 | $9.24 |
Enterprise Value | $631.90B | $1.80B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Tripadvisor (TRIP) trades at $14.38, down 1.37% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but maintains strong gross margins of 91.95%. Recent $700 million sale of TheFork to American Express provides capital flexibility while focusing on core travel experiences business. Revenue growth remains modest at $1.89B in 2025 with net margin improving to 2.11%.
Outlook remains cautious with analyst consensus at Hold (60.72%) and $13.87 price target below current levels. The stock faces headwinds from competitive pressures and macroeconomic uncertainty, though the strategic divestiture and travel recovery trends offer potential upside. Key risks include execution challenges and market volatility amid mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
